Alastair Garfield - 01 Feb 2026 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Role: Chief Scientific Officer
Signature: /s/ Stephen Vander Stoep, attorney-in-fact for Alastair Garfield
Issuer symbol: RYTM
Transactions as of: 01 Feb 2026
Net transactions value: -$220,814
Form type: 4
Filing time: 03 Feb 2026, 16:31:57 UTC
Previous filing: 03 Jul 2025
Next filing: 13 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Garfield Alastair	Chief Scientific Officer	222 BERKELEY STREET, 12TH FLOOR, BOSTON	/s/ Stephen Vander Stoep, attorney-in-fact for Alastair Garfield	03 Feb 2026	0002027261

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RYTM	Common Stock	Options Exercise		+6,663	+213%		9,789	01 Feb 2026	Direct	F1
transaction	RYTM	Common Stock	Tax liability	$220,814	-2,026	-21%	$108.99	7,763	01 Feb 2026	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RYTM	Restricted Stock Units	Options Exercise	$0	-6,663	-25%	$0.000000	19,987	01 Feb 2026	Common Stock	6,663		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2	These shares were withheld for payment of the withholding taxes upon the vesting of the restricted stock units reported herein.
F3	The restricted stock units vest as to 25% of the total shares on each of February 1, 2026, February 1, 2027, February 1, 2028 and February 1, 2029. The restricted stock units have no expiration date.